HDA taps AAM's Chip Davis as CEO

Press enter to search
Close search
Open Menu

HDA taps AAM's Chip Davis as CEO

By Sandra Levy - 02/10/2020

The Healthcare Distribution Alliance has new leadership. The company has named Chester "Chip" Davis president and CEO. Davis, whose new appointment is effective in March, most recently was president and CEO of the Association for Accessible Medicines. 

As president and CEO of HDA, Davis will oversee the organization's day-to-day operations and work with the HDA board to set the strategic vision to guide the organization forward. He will be responsible for ensuring that HDA's members have the greatest possible advocacy voice in legislation, regulation and policy. Davis will be based at HDA’s headquarters and will report to the HDA board of directors.

Chip Davis

"Chip’s leadership experience and strong advocacy background in healthcare make him the perfect candidate to lead HDA," said Greg Drew, president of Value Drug and chairman of the HDA board of directors. "Chip understands the complex relationships and challenges of our industry and member companies and has a deep appreciation for ensuring that all patients receive the right medicines, at the right time, safely and efficiently. I am excited for HDA's path forward."

With Davis leaving AAM, the generic drug industry trade organization appointed senior vice president and general counsel CEO as the board searches for a permanent replacement. "The generic drug and biosimilars industry owes Chip a debt of gratitude for his leadership and hard work on behalf of patients who are struggling with the high cost of health care," Francer said. "I am honored to continue to support the mission of AAM's member companies to enhance access to life-saving medicines and deliver great value to patients and taxpayers."

Davis took the helm of AAM in 2015, when the trade group was known as the Generic Pharmaceutical Association. In the ensuing years, he oversaw the organization's rebrand and focused on advocating on several issues impacting the generic drug industry and patient access to affordable medicines, including the reauthorization of the generic and biosimilar user fee agreements and Congressional passage of the CREATES Act. Davis' tenure also saw AAM membership increase while more than doubling its operating budget. 

Davis also brings to AAM experience with the Pharmaceutical Research and Manufacturers of America and AstraZeneca. 

"I have long held great respect and appreciation for pharmaceutical distributors and the critical role they play to ensure the safety, reliability and value of medicine and medical products as they move through the ecosystem, from manufacturer to provider to patient, to achieve the ultimate objective of ensuring patients have access to the treatments they need. I am excited to join them as president and CEO to be able to convey their value, and the vital role they play," said  Davis. "I look forward to working with the entire HDA team and all of HDA’s members as we collectively work to navigate the ever-changing dynamics of the U.S. healthcare system."

Related Topics